Doz, F., van Tilburg, C. M., Geoerger, B., Nysom, K., Øra, I., Boni, V., Chisholm, J., Chung, H. C., DuBois, S. G., Melcón, S. G., Gerber, N. U., Goto, H., Grilley-Olsen, J. E., Hansford, J. R., Hong, D. S., Italiano, A., Kang, H. J., Capra, M., Schulte, J. H., Stefanowicz, J., Tahara, M., Ziegler, D. S., Gavrilovic, I. T., Norenberg, R., Dima, L., De La Cuesta, E., Laetsch, T. W., Drilon, A., & Perreault, S. (2021). cTNI-58. EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT AND PEDIATRIC PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION-POSITIVE PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS. Neuro-oncology, 23, vi73–vi74. http://access.bl.uk/ark:/81055/vdc_100146090265.0x00002f